Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Deena Shelton

Nurse Practitioner, Psychiatric/Mental Health Saint Joseph, MO Nurse Practitioner

NPI 1821742503 CMS profile 11354083

724 N 22Nd St, Saint Joseph, MO 64506

Open in the dashboard

General payments

$6,755

353 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Deena Shelton of Saint Joseph, MO is reported in the CMS Open Payments database as having received $6,755 across 353 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,982 98
2024 General $2,164 135
2023 General $2,147 97
2022 General $462 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deena Shelton
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Deena Shelton were reported at $1,982. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Deena Shelton Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $166 $54–$482 $132
2022 $462 $195 $66–$559 $149
2023 $2,147 $233 $82–$673 $160
2024 $2,164 $236 $84–$688 $164
2025 $1,982 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Teva Pharmaceuticals USA, Inc. $1,607 103 payments
  2. Janssen Pharmaceuticals, Inc $1,412 55 payments
  3. Otsuka America Pharmaceutical, Inc. $1,141 52 payments
  4. AbbVie, Inc. $859 50 payments
  5. ITI, Inc. $570 36 payments
  6. Vanda Pharmaceuticals Inc. $380 16 payments
  7. Neurocrine Biosciences, Inc. $255 14 payments
  8. Lundbeck LLC $125 6 payments
  9. Alkermes, Inc. $123 4 payments
  10. E.R. Squibb & Sons, L.L.C. $100 6 payments
  11. Other $183 11 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $6,432 350 payments
  2. Education $323 3 payments
Products named General payments · program years 2022–2025
  1. REXULTI $866 40 payments
  2. Austedo XR $853 58 payments
  3. INVEGA SUSTENNA $830 25 payments
  4. VRAYLAR $671 39 payments
  5. ABILIFY MAINTENA $528 24 payments
  6. SPRAVATO $457 29 payments
  7. FANAPT $380 16 payments
  8. INVEGA TRINZA $325 6 payments
  9. CAPLYTA $316 19 payments
  10. INGREZZA $255 14 payments
  11. Other $2,126 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

1,707

Median for Nurse Practitioner: 389

Drug cost

$596,692

Median for Nurse Practitioner: $21,885

Branded share of claims

25.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Spravato Esketamine Hcl Brand 197 $248,283
Austedo Deutetrabenazine Brand 14 $138,257
Abilify Maintena Aripiprazole Brand 21 $62,291
Aristada Aripiprazole Lauroxil Brand 13 $51,999
Vraylar Cariprazine Hcl Brand 24 $39,938
Vivitrol Naltrexone Microspheres Brand 13 $23,004
Trintellix Vortioxetine Hydrobromide Brand 12 $6,427
Aripiprazole Generic 40 $2,352
Propranolol Hcl Generic 98 $2,061
Quetiapine Fumarate Generic 88 $1,615

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$4,450

Medicare's payments for the services billed

Medicare patients

22

Average age 63

Services billed

78

11 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Depression 68%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $464
$464 14 —
VRAYLAR
  • AbbVie, Inc. $399
$399 24 —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $219
$219 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $125
  • Lundbeck LLC $92
$216 — —
CAPLYTA
  • ITI, Inc. $170
$170 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

353 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record